Table of Contents
Pathology Research International
Volume 2012, Article ID 851432, 8 pages
http://dx.doi.org/10.1155/2012/851432
Clinical Study

Immunohistochemical Expression of Platelet-Derived Growth Factor Receptors in Ovarian Cancer Patients with Long-Term Follow-Up

1Department of Oncology, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark
2Institute for Regional Health Services Research, University of Southern Denmark, 5230 Odense, Denmark
3Department of Pathology, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark

Received 28 June 2012; Revised 28 August 2012; Accepted 28 August 2012

Academic Editor: Paulette Mhawech-Fauceglia

Copyright © 2012 Christine Vestergaard Madsen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Bookman, “First-line randomized trials: revisiting the Ptolemaic universe,” International Journal of Gynecological Cancer, vol. 18, no. 1, pp. 47–52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. T. Thigpen, “Chemotherapy for advanced ovarian cancer: overview of randomized trials,” Seminars in Oncology, vol. 27, no. 3, pp. 11–16, 2000. View at Google Scholar · View at Scopus
  3. T. J. Perren, A. M. Swart, J. Pfisterer et al., “A phase 3 trial of bevacizumab in ovarian cancer,” New England Journal of Medicine, vol. 365, no. 26, pp. 2484–2496, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. A. Burger, M. F. Brady, M. A. Bookman et al., “Incorporation of bevacizumab in the primary treatment of ovarian cancer,” The New England Journal of Medicine, vol. 365, pp. 2473–2483, 2011. View at Publisher · View at Google Scholar
  5. M. P. Smerdel, K. D. Steffensen, M. Waldstrøm, I. Brandslund, and A. Jakobsen, “The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab,” Gynecologic Oncology, vol. 118, no. 2, pp. 167–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. A. A. Garcia, H. Hirte, G. Fleming et al., “Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia,” Journal of Clinical Oncology, vol. 26, no. 1, pp. 76–82, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. R. A. Burger, M. W. Sill, B. J. Monk, B. E. Greer, and J. I. Sorosky, “Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5165–5171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Ferrara and R. S. Kerbel, “Angiogenesis as a therapeutic target,” Nature, vol. 438, no. 7070, pp. 967–974, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. C. H. Heldin and B. Westermark, “Mechanism of action and in vivo role of platelet-derived growth factor,” Physiological Reviews, vol. 79, no. 4, pp. 1283–1316, 1999. View at Google Scholar · View at Scopus
  10. B. Westermark, A. Siegbahn, C. H. Heldin, and L. Claesson-Welsh, “B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 1, pp. 128–132, 1990. View at Publisher · View at Google Scholar · View at Scopus
  11. C. H. Heldin, A. Ostman, and C. H. Heldin, “PDGF and vessel maturation,” Recent Results in Cancer Research, vol. 180, pp. 103–114, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Lindahl, B. R. Johansson, P. Levéen, and C. Betsholtz, “Pericyte loss and microaneurysm formation in PDGF-B-deficient mice,” Science, vol. 277, no. 5323, pp. 242–245, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Dong, J. Grunstein, M. Tejada et al., “VEGF-null cells require PDGFR α signaling-mediated stromal fibroblast recruitment for tumorigenesis,” EMBO Journal, vol. 23, no. 14, pp. 2800–2810, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Forsberg, I. Valyi-Nagy, C. H. Heldin, M. Herlyn, and B. Westermark, “Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 2, pp. 393–397, 1993. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Cao, M. A. Björndahl, P. Religa et al., “PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis,” Cancer Cell, vol. 6, no. 4, pp. 333–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Abdollahi and J. Folkman, “Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy,” Drug Resistance Updates, vol. 13, no. 1-2, pp. 16–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Fredriksson, H. Li, and U. Eriksson, “The PDGF family: four gene products form five dimeric isoforms,” Cytokine and Growth Factor Reviews, vol. 15, no. 4, pp. 197–204, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Andrae, R. Gallini, and C. Betsholtz, “Role of platelet-derived growth factors in physiology and medicine,” Genes and Development, vol. 22, no. 10, pp. 1276–1312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Gerhardt and H. Semb, “Pericytes: gatekeepers in tumour cell metastasis?” Journal of Molecular Medicine, vol. 86, no. 2, pp. 135–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C. H. Heldin, A. Östman, and L. Rönnstrand, “Signal transduction via platelet-derived growth factor receptors,” Biochimica et Biophysica Acta, vol. 1378, no. 1, pp. F79–F113, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Chen, Y. Shi, C. Y. Jiang et al., “Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma,” International Journal of Biological Markers, vol. 26, no. 2, pp. 108–116, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Donnem, S. Al-Saad, K. Al-Shibli, S. Andersen, L. T. Busund, and R. M. Bremnes, “Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells,” Journal of Thoracic Oncology, vol. 3, no. 9, pp. 963–970, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. M. L. Fjällskog, O. Hessman, B. Eriksson, and E. T. Janson, “Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas,” Acta Oncologica, vol. 46, no. 6, pp. 741–746, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Gockel, M. Moehler, K. Frerichs et al., “Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer,” Oncology Reports, vol. 20, no. 4, pp. 845–850, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Kitadai, T. Sasaki, T. Kuwai et al., “Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential,” International Journal of Cancer, vol. 119, no. 11, pp. 2567–2574, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. W. M. Ongkeko, X. Altuna, R. A. Weisman, and J. Wang-Rodriguez, “Expression of protein tyrosine kinases in head and neck squamous cell carcinomas,” American Journal of Clinical Pathology, vol. 124, no. 1, pp. 71–76, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Paulsson, T. Sjöblom, P. Micke et al., “Prognostic significance of stromal platelet-derived growth factor β-receptor expression in human breast cancer,” American Journal of Pathology, vol. 175, no. 1, pp. 334–341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. M. Apte, C. D. Bucana, J. J. Killion, D. M. Gershenson, and I. J. Fidler, “Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines,” Gynecologic Oncology, vol. 93, no. 1, pp. 78–86, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. M. B. Dabrow, M. R. Francesco, F. X. McBrearty, and S. Caradonna, “The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium,” Gynecologic Oncology, vol. 71, no. 1, pp. 29–37, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Henriksen, K. Funa, E. Wilander, T. Backstrom, M. Ridderheim, and K. Oberg, “Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms,” Cancer Research, vol. 53, no. 18, pp. 4550–4554, 1993. View at Google Scholar · View at Scopus
  31. H. Lassus, H. Sihto, A. Leminen et al., “Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma,” British Journal of Cancer, vol. 91, no. 12, pp. 2048–2055, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Matei, R. E. Emerson, Y. C. Lai et al., “Autocrine activation of PDGFRα promotes the progression of ovarian cancer,” Oncogene, vol. 25, no. 14, pp. 2060–2069, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. R. E. Schmandt, R. Broaddus, K. H. Lu et al., “Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium,” Cancer, vol. 98, no. 4, pp. 758–764, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. S. P. Wilczynski, Y. Y. Chen, W. Chen, S. B. Howell, J. E. Shively, and D. S. Alberts, “Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRα, and PDGFRβ in ovarian cancers,” Human Pathology, vol. 36, no. 3, pp. 242–249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Yamamoto, H. Tsuda, M. Takano et al., “Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors,” Modern Pathology, vol. 21, no. 2, pp. 115–124, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. R. A. Burger, “Overview of anti-angiogenic agents in development for ovarian cancer,” Gynecologic Oncology, vol. 121, no. 1, pp. 230–238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Schmitt and D. Matei, “Platelet-derived growth factor pathway inhibitors in ovarian cancer,” Clinical Ovarian Cancer, vol. 1, no. 2, pp. 120–126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Jakobsen, K. Bertelsen, J. E. Andersen et al., “Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study,” Journal of Clinical Oncology, vol. 15, no. 1, pp. 193–198, 1997. View at Google Scholar · View at Scopus
  39. C. V. Madsen, K. D. Steffensen, M. Waldstrøm, and A. Jakobsen, “The prognostic value of syndecan-1 in ovarian cancer patients with long-term follow up,” Clinical Ovarian Cancer, vol. 4, no. 1, pp. 12–18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Shimizu, S. Kamoi, S. Amada, F. Akiyama, and S. G. Silverberg, “Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up,” Cancer, vol. 82, pp. 893–901, 1998. View at Google Scholar
  41. J. R. Landis and G. G. Koch, “The measurement of observer agreement for categorical data,” Biometrics, vol. 33, no. 1, pp. 159–174, 1977. View at Google Scholar · View at Scopus
  42. M. Köbel, S. E. Kalloger, N. Boyd et al., “Ovarian carcinoma subtypes are different diseases: implications for biomarker studies,” PLoS Medicine, vol. 5, no. 12, p. e232, 2008. View at Publisher · View at Google Scholar · View at Scopus